Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer

An important clinical challenge in prostate cancer therapy is the inevitable transition from androgen-sensitive to castration-resistant and metastatic prostate cancer. Albeit the androgen receptor (AR) signaling axis has been targeted, the biological mechanism underlying the lethal event of androgen...

Full description

Bibliographic Details
Main Authors:	Li, Ping, Yang, Ru, Gao, Wei-Qiang
Format:	Online
Language:	English
Published:	BioMed Central 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975176/

id	pubmed-3975176
recordtype	oai_dc
spelling	pubmed-39751762014-04-05 Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer Li, Ping Yang, Ru Gao, Wei-Qiang Review An important clinical challenge in prostate cancer therapy is the inevitable transition from androgen-sensitive to castration-resistant and metastatic prostate cancer. Albeit the androgen receptor (AR) signaling axis has been targeted, the biological mechanism underlying the lethal event of androgen independence remains unclear. New emerging evidences indicate that epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) play crucial roles during the development of castration-resistance and metastasis of prostate cancer. Notably, EMT may be a dynamic process. Castration can induce EMT that may enhance the stemness of CSCs, which in turn results in castration-resistance and metastasis. Reverse of EMT may attenuate the stemness of CSCs and inhibit castration-resistance and metastasis. These prospective approaches suggest that therapies target EMT and CSCs may cast a new light on the treatment of castration-resistant prostate cancer (CRPC) in the future. Here we review recent progress of EMT and CSCs in CRPC. BioMed Central 2014-03-12 /pmc/articles/PMC3975176/ /pubmed/24618337 http://dx.doi.org/10.1186/1476-4598-13-55 Text en Copyright © 2014 Li et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Li, Ping Yang, Ru Gao, Wei-Qiang
spellingShingle	Li, Ping Yang, Ru Gao, Wei-Qiang Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer
author_facet	Li, Ping Yang, Ru Gao, Wei-Qiang
author_sort	Li, Ping
title	Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer
title_short	Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer
title_full	Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer
title_fullStr	Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer
title_full_unstemmed	Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer
title_sort	contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer
description	An important clinical challenge in prostate cancer therapy is the inevitable transition from androgen-sensitive to castration-resistant and metastatic prostate cancer. Albeit the androgen receptor (AR) signaling axis has been targeted, the biological mechanism underlying the lethal event of androgen independence remains unclear. New emerging evidences indicate that epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) play crucial roles during the development of castration-resistance and metastasis of prostate cancer. Notably, EMT may be a dynamic process. Castration can induce EMT that may enhance the stemness of CSCs, which in turn results in castration-resistance and metastasis. Reverse of EMT may attenuate the stemness of CSCs and inhibit castration-resistance and metastasis. These prospective approaches suggest that therapies target EMT and CSCs may cast a new light on the treatment of castration-resistant prostate cancer (CRPC) in the future. Here we review recent progress of EMT and CSCs in CRPC.
publisher	BioMed Central
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975176/
_version_	1612073990847725568

Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer

Similar Items